Study Review – Inhibition of progression with guselkumab in active psoriatic arthritis: The phase 3b APEX study

As part of our ongoing aim to bring you reports of new developments, we have added a study review on APEX, which is an ongoing phase 3b, double-blind, placebo-controlled trial assessing the effects of guselkumab on clinical and radiographic outcomes in active psoriatic arthritis.

Independent commentary for the review has been provided by Associate Professor Andrew Östör, a Consultant Rheumatologist at Cabrini Medical Centre and an Associate Professor at Monash University, Melbourne & Australian National University, Canberra. He is also a Principal Investigator at Emeritus Research, Melbourne, Australia.